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ADS: alginate/dextran sulfate 
NPs: nanoparticles 
LD: laser diffractometry 
CD: circular dichroism  
DMEM: dulbecco’s modified eagle medium  
FBS: fetal bovine serum  
Cryo-SEM: cryo-scanning electron microscopy 
ANOVA: one way analysis of variance  
LOD: limit of detection 
DLS: dynamic light scattering 
ELS: electrophoretic light scattering  
PI: polydispersity index  
w/o: water/oil 
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ABSTRACT 16 
Alginate-dextran sulfate (ADS) microgel has been used to protect insulin from 17 
gastrointestinal attack and as a carrier to promote insulin permeation through intestinal 18 
epithelium. The throughput of ADS submicron particles generation by 19 
emulsification/internal gelation is limited by its wide size distribution.  20 
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The aim of this work was to study the recovery protocol influence on ADS particles 21 
through the determination of its impact on particles’ size distribution and bioactivity. 22 
ADS particles showed a wide and multimodal distribution, characterized by a high 23 
aggregation phenomenon. In an attempt to reverse particles’ tendency to aggregate and 24 
to homogenize particle size ADS populations were submitted to ultrasonication, while 25 
particle size distribution, physical and chemical stability, and the bioactivity of 26 
entrapped insulin were investigated. After ultrasonication a narrower particle population 27 
shifted to the nanoscale, with higher physical stability and significant insulin bioactivity 28 
was obtained. Emulsification internal/gelation followed by ultrasonication constituted a 29 
valid strategy to obtain ADS particles at the submicron range, with high stability and 30 
without significantly compromising insulin bioactivity, so offering promises, under 31 
previously well established conditions, to evaluate impact of ADS particle’s size on 32 
biopharmaceutical and pharmacokinetics phases. 33 
 34 
KEYWORDS: hydrogels; particle size; physical stability; ultrasound; emulsion; In vitro 35 
models. 36 
 37 
1. Introduction 38 
Microgels have gained considerable attention in recent years as one of the most 39 
promising nanoparticulate drug delivery systems owing to their unique potentials via 40 
combining microgel’s hydrophilicity and extremely high water content with a nanosize 41 
scale. Particles’ size is a keyrole in biomedical applications, with given influence on 42 
biorecognition (Hwang, Truong & Sim, 2012), biodistribution (Hirn et al., 2011), 43 
bioadhesion (Hasani, Pellequer & Lamprecht, 2009), biocompatibility (Akbar, 44 
Mohamed, Whitehead & Azzawi, 2011), and biodegradation (Cui, Hunter, Yang, Chen 45 
& Gan, 2011). Smaller particles may penetrate cells by passing directly through the cell 46 
membrane or infiltrate between cells, translocate to new sites and to the blood/lymph 47 
and thereby target organs away from their portal of entry (Geiser et al., 2005). 48 
Controlled release experiments with hydrophobic dexamethasone and hydrophilic 49 
vitamin C used as encapsulant models showed that for these small molecular drugs, the 50 
loading amount was mainly determined by the surface area of the nanoparticles (NPs), 51 
and the subsequent release of the drug dramatically decreased with the increasing of the 52 
particle size (Gan et al., 2012). Therefore, emulsification/internal gelation technique, 53 
initially conceived for microparticles preparation (Poncelet, Lencki, Beaulieu, Halle, 54 
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Neufeld & Fournier, 1992), rapidly spurred interest in extending it into the submicron 55 
range. 56 
Recent works concerning insulin delivery systems have shown good characteristics in 57 
terms of insulin chemical stability and bioactivity maintenance (Luo et al., 2012; Zhang 58 
et al., 2010), however most of them are for subcutaneous injection (Al-Tahami, Oak & 59 
Singh, 2010; Chen, Wu, Guo, Xin & Li, 2011; Oak & Singh, 2011) and use synthetic 60 
instead of biopolymers. Insulin-loaded alginate-dextran sulfate (ADS) particles prepared 61 
by emulsification/internal gelation constitute a promising controlled delivery system for 62 
oral route (Reis, Veiga, Ribeiro, Neufeld & Damge, 2008). The objective of insulin 63 
entrapment into the polymeric matrix is to minimize protein denaturation, stabilizing 64 
and maintaining its physiological activity during both particle manufacturing and drug 65 
release (Reis, Ribeiro, Houng, Veiga & Neufeld, 2007; Silva, Ribeiro, Figueiredo, 66 
Goncalves & Veiga, 2006), namely in the passage through the stomach in order to 67 
enhance its bioavailability (Krishnankutty, Mathew, Sedimbi, Suryanarayan & Sanjeevi, 68 
2009).  69 
ADS submicron particles generation by emulsion and internal gelation is a scalable 70 
method of encapsulation and is based on the release of calcium ion from an acid soluble 71 
calcium salt in emulsified ADS solution. This is achieved by acidification with an oil-72 
soluble acid, which partitions to the dispersed aqueous alginate phase, releasing soluble 73 
calcium and initiating gelation. 74 
One of the limitations of this technique lies in the ability to obtain monodispersed 75 
particles’ populations. ADS particles showed polydispersed populations, characterized 76 
by a wide distribution of size values which derive from nano- and microparticles and 77 
also aggregates coexistence (Reis, Ribeiro, Houng, Veiga & Neufeld, 2007; Reis, 78 
Veiga, Ribeiro, Neufeld & Damge, 2008), which is characteristic of emulsification 79 
methods using biodegradable polymers (Gaumet, Gurny & Delie, 2009). Moreover, the 80 
reduced size of particles together with their large surface area, can lead to particle-81 
particle aggregation during storage and transportation of particle dispersion.  82 
ADS particles were successfully produced by emulsification/internal gelation and 83 
recovered by using a washing medium composed of acetate buffer pH 84 
4.5/isopropanol/acetone/hexane coupled to centrifugation (Reis, Ribeiro, Neufeld & 85 
Veiga, 2007). Even though these solvents levels were below the limits accepted in the 86 
pharmaceutical field for collected particles, a recovery protocol with no solvents or with 87 
the minimum use of them is an increasing value of the technique. Acetate buffer 88 
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contributes to retain insulin in NPs network while the use of solvents aims to collect 89 
microgel from biphasic medium. Acetone is indispensable due to its low viscosity and 90 
also its miscibility with both aqueous phase and the predominant hydrophobic emulsion 91 
phase medium, conferring high mobility to the particles and allow a successful 92 
particles’ recovery.  93 
The first concern in ADS particles produced by the present method is the necessity of an 94 
approach to size-fraction particles’ populations, to obtain a more detailed description 95 
and better understanding of these particles. To attain this aim, a recovery protocol of 96 
microgel particles, based on the coupling of centrifugation and acetone as washing 97 
medium was used. Whether ultrasonication can disaggregate collected microgel while 98 
keeping insulin bioactivity was investigated. Physical stability was determined through 99 
sedimentation tests and zeta potential; and chemical stability was evaluated using 100 
circular dichroism (CD) and HPLC-MS analysis. Submicron particles with a narrow 101 
size distribution, with high insulin content, retention of insulin bioactivity and good 102 
physical and maintained chemical stability were aimed. 103 
 104 
2. Materials and methods 105 
2.1. Materials 106 
Sodium alginate (viscosity of 2% solution at 25°C, 250cps) extracted from brown algae, 107 
dextran sulfate (5kDa), Victoria-blue R and Phosphotungstic acid, Sorbitane 108 
monooleate (Span 80®) were purchased from Sigma-Aldrich (Steinheim, Germany). 109 
Ultrafine calcium carbonate (Setacarb 06 calcium) was supplied from Omya (Organ, 110 
France). Insulin (Actrapid® Insulin) was kindly donated from Hospitais da Universidade 111 
de Coimbra – Coimbra, Portugal, supplied by Novo Nordisk (Bagsvaerd, Denmark). 112 
Paraffin oil was purchased from Fagron (Terrasa, Spain). Dulbecco’s Modified Eagle 113 
Medium (DMEM), fetal bovine serum (FBS), L-glutamine and Penicilin/Streptomycin 114 
were purchased from Lonza (Visp, Switzerland). 10x solution of trypsin-EDTA was 115 
prepared from porcine trypsin and EDTA powders obtained from Sigma-Aldrich 116 
(Steinheim, Germany). Paraformaldehyde was purchased from Merck (Darmstadt, 117 
Germany). A Thermo Scientific Pierce® BCA Protein Assay Kit was obtained from 118 
Thermo Scientific (Rockford, Illinois, USA). Fast-activated cell based AKT (FACE-119 
AKT) ELISA kits were manufactured by Active Motif (Carlsbad, California, USA) and 120 
purchased from Frilabo (Maia, Portugal). All other reagents were of analytical grade 121 
and were used as received. 122 
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 123 
2.2. Methods 124 
2.2.1. Preparation of alginate-dextran sulfate particles 125 
ADS particles were prepared according to an adaptation from the emulsification/internal 126 
gelation technique previously described (Poncelet, Lencki, Beaulieu, Halle, Neufeld & 127 
Fournier, 1992). An aqueous solution of low viscosity sodium alginate (2%, w/v) and 128 
dextran sulfate (0.75%, w/v) was prepared by orbital shaking. Insulin (100 IU/mL, 129 
10mL) was mixed into ADS solution. An aqueous suspension of calcium carbonate 130 
(5%, w/v) was sonicated for 30 min and then it was dispersed into the ADS-insulin 131 
solution (calcium-alginate ratio, 7%, w/w). The resulting mixture was emulsified within 132 
paraffin oil with sorbitane monooleate (1.5%, v/v) by impeller-stirring homogenization 133 
(1600 rpm, 30 min). Gelation was triggered in situ by the dissolution of calcium 134 
complex, as a consequence of the addition of 20 mL of paraffin oil containing glacial 135 
acetic acid (molar ratio acid-calcium, 3.5) during 15 min, with continued stirring. 136 
Unloaded particles were prepared as controls. Each batch was prepared in triplicate.  137 
 138 
2.2.2. Particle recovery  139 
Oil-dispersed ADS particles were recovered through an extraction with a medium 140 
consisting of acetone with acetate buffer (pH 4.5) (1:10, v/v) (USP 30-NF 25). ADS 141 
particles were subjected to extra washing cycles consisting of coupling washing 142 
medium extraction/centrifugation until no more oil was found under microscopic 143 
observation. These particles were stored at 4°C in acetate buffer.  144 
 145 
2.2.3. Morphological analysis 146 
Morphology of hydrated particles stained with Victoria-blue R was monitored by 147 
optical microscopi  observation using an optical microscope equipped with a Digital 148 
Sight DS-U2 microscope camera controller. The shape and surface and mass 149 
spectroscopy of hydrated particles were analysed by Field Environmental (FE)-Cryo-150 
SEM with EDS-JEOL JSM 6301F scanning microscope (Oxford INCA Energy 350, 151 
Gatan Alto 2500). Phosphotungstic acid-stained particles were frozen using liquid 152 
nitrogen slush (-210 °C) under vacuum, to allow their fracture in order to obtain a fresh 153 
and clean surface for examination. After that, samples were sublimated at -90°C for 4 154 
min to remove top layers of water molecules. Finally, samples were sputter coated with 155 
gold/palladium for 40 seconds, followed by image capturing.  156 
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 157 
2.2.4. Determination of Recovery Yield 158 
Recovery yield of the process was assessed by measuring the ratio between isolated 159 
particles and total recovered particles (v/v), according to the following equation Eq. (A): 160 
 161 
Recovery Yield (%) = (Volume of isolated particles/Total recovered particles)×100 (A) 162 
 163 
2.2.5. Determination of Insulin Content 164 
Insulin was extracted from particles firstly by treatment with sodium citrate 2M (1/2, 165 
v/v) followed by orbital shaking. Insulin concentration was determined using Pierce® 166 
BCA Protein Assay Kit.  Unloaded particles were used as control and assay was 167 
performed in triplicate. Calibration curve was made using different concentrated 168 
solutions of insulin in the same medium. Insulin content (%) was assessed according to 169 
the equation below Eq. (B):  170 
 171 
Insulin Content (%) = (Insulin mass in isolated particles/Total recovered insulin mass) 172 
× 100 (B) 173 
  174 
2.2.6. Particle size analysis 175 
Size distribution analysis was performed by laser diffractometry (LD) using a laser 176 
diffraction particle size analyser (Beckman Coulter® LS 13 320, Miami, FL, USA) with 177 
polarization intensity differential scattering (PIDS). The real refractive index and the 178 
imaginary refractive index were set to 1.36 and 0.01, respectively. Three measurements 179 
of 90s were used to obtain the LD data, which were expressed using volume 180 
distributions, and given as diameter values corresponding to percentiles of 10%, 50% 181 
and 90%, using the Mie theory. The span value is a statistical parameter useful to 182 
characterize the particle size distribution, which is obtained through the following 183 
equation (Wissing, Kayser & Muller, 2004):  184 
 185 
Span = (d90%−d10%) / d50%. 186 
 187 
The particle size of selected samples was additionally investigated by dynamic light 188 
scattering (DLS) using other particle size analyser (DelsaNano C, Beckman Coulter 189 
Delsa™). Mean diameter, size distribution and polydispersity index (PI) (which 190 
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measures the width of the size distribution) of pH 4.5 buffered particle’s suspensions 191 
were determined in triplicate at 25°C with an angle measurement of 60°. Previous 192 
measurement, the dispersions were diluted with acetate buffer to an appropriate 193 
concentration of particles to avoid multiple scattering before. One measurement was 194 
performed after an equilibration period of 3 min for 300 s at 25°C to obtain the results.  195 
Both instruments were routinely checked and calibrated using standard latex particle kit 196 
(Beckman Coulter, Inc.). 197 
 198 
2.2.7. In vitro release studies 199 
In vitro release behavior was assayed by incubating 5 mL of ADS particles suspension 200 
in 5 mL of HCl buffer at pH 1.2 (British Pharmacopoeia, 2010), under magnetic stirring 201 
(100 rpm, 2 h), simulating stomach conditions without enzymes under sink conditions. 202 
To simulate the progress of particles moving from the stomach into the upper small 203 
intestine, the buffer was changed to higher pH after 2 h min. Particles were centrifuged 204 
(12500 g, 10 min), then resuspended in 10 mL phosphate buffer at pH 6.8 (British 205 
Pharmacopoeia, 2010)), under magnetic stirring (100 rpm) during 10 h. Samples at 206 
appropriate intervals were withdrawn and replaced by the same volume of fresh 207 
incubation medium, and were assayed for insulin content in the supernatant after 208 
centrifugation (12500 g, 10 min), using Pierce® BCA Protein Assay Kit. All the 209 
operations were made in triplicate. 210 
2.2.8. Ultrasonication exposure 211 
Ultrasonication was applied with Ultrasonicator Sonics® VCX130 (Sonics & Materials, 212 
USA) for two five-minute cycles with 52W, after dilution of 10 mL of ADS particles 213 
into 1:1 with acetate buffer, in order to obtain a narrower ADS particles’ population. 214 
The temperature was controlled around 25°C by using an ice bath.   215 
 216 
2.2.9. Zeta potential analysis 217 
Zeta potential measurements, which reflect the electric charge on the particle surface, 218 
were taken by electrophoretic light scattering (ELS) using a Nano Zeta Potential 219 
Analyser (DelsaNano C, Beckman Coulter Delsa™). Measurements were taken in a 220 
Flow Cell (Beckman Coulter Delsa™) at 25°C and acetate buffer solution pH 4,5 was 221 
used as diluent to proper concentration. Zeta potential values are presented as means of 222 
triplicate runs per sample. The instrument was routinely checked and calibrated using 223 
mobility standard (Beckman Coulter, Inc.). 224 
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 225 
2.2.10. Sedimentation tests 226 
In sedimentation tests, an analytical centrifugation system detects the intensity of 227 
transmitted light over the entire sample length as function of time and position, while 228 
the sample was being centrifuged (Lerche, 2002). Accelerated physical stability testing 229 
of ADS particles was performed using a LUMisizer® (L.U.M. GmbH, Germany) 230 
centrifuge, working at 2000 rpm, during 128 min and 25ºC, which measured the 231 
transmission variations of particles’ suspensions under centrifugation against time. All 232 
data were stored and displayed in real time as a function of radial position, enabling 233 
analysis of the dispersion characteristics. 234 
 235 
2.2.11. Insulin bioactivity in vitro assay   236 
NIH/3T3 fibroblast cell line was cultivated in DMEM with 4.5 g/L glucose 237 
supplemented with 10% heat inactivated FBS, 2mM L-glutamine, 100 U/mL penicillin, 238 
100 U/mL streptomycin. The cells were passed 1:4 twice a week at 80% confluence 239 
with 0.05% trypsin-0.02%EDTA. To prepare the cells for the FACETM AKT assays the 240 
fibroblasts were trypsin-released, washed, and counted with a hemocytometer with 241 
trypan blue viability staining. The cells were seeded in flat-bottom, tissue culture treated 242 
96-well plates at a density of 3.5x104 cells/well in 200μL of complete medium. Two 243 
identical plates were prepared, one to measure AKT phosphorylation and the second for 244 
the assessment of the total AKT protein under the same conditions. The plates were 245 
incubated overnight (37 ºC/5% CO2) to achieve 80% confluence. Prior to stimulating 246 
the cells with insulin, the medium was aspirated and the cells were washed twice with 247 
PBS. The cells were then incubated (37 ºC/5% CO2) in serum-free starvation medium 248 
(DMEM with 4.5 g/L glucose, 2 mM L-glutamine, 100 U/mL penicillin, 100 U/mL 249 
streptomycin) for 8h. Subsequently, the cells were exposed to either: (i) active, free 250 
insulin or (ii) insulin released from the ADS particles (into sodium citrate 2M, as 251 
described before for insulin determination content assay). The samples were then 252 
diluted to 150nM in starvation medium based on the total protein content measured 253 
using UV absorbance, as described previously. Blank particles without insulin, treated 254 
identically, were used as negative controls. For each trial, a standard curve was prepared 255 
using free insulin with concentrations ranging from 50-200 nM in starvation medium 256 
and citrate buffer adjusted to the percentage equivalent to the volume inherent to the 257 
samples. The cells were stimulated for 10 min with 200 μL of the insulin-containing 258 
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samples applied to each well. At the end of the stimulation period, the medium was 259 
aspirated and the cells were immediately fixed in 4% paraformaldehyde in PBS. The 260 
plates were incubated at room temperature for 20 min and stored at 4 ºC until the next 261 
step of the assay. Insulin bioactivity was determined by quantifying the ratio of p-AKT 262 
protein to total AKT protein using the FACETM-AKT immunoassay, normalized to the 263 
total cell count, according to the manufacturer’s instructions, and interpolated into the 264 
standard curve. Briefly, the fixed cells were washed 3 times in washing buffer and 265 
incubated overnight at 4 ºC in primary antibody solution specific for p-AKT or total 266 
AKT. After 3 washing steps, the HRP-conjugated anti-rabbit IgG was applied for 1 h, 267 
following which the substrate/developing solution was added to initiate the colorimetric 268 
reaction. After 20 min, the stop solution was added and the absorbance was measured at 269 
room temperature using a plate reader spectrophotometer (Synergy 2 Multi-Mode 270 
Microplate Reader, Biotek) at 450 nm corrected by the absorbance at 655 nm. For each 271 
sample, the absorbance data for both p-AKT and total AKT were normalized to the total 272 
cell number per well by staining with crystal violet and measuring the absorbance at 273 
595 nm. After normalization to the total cell count, the ratio of p-AKT to total AKT was 274 
calculated for each sample condition as a measure of the extent of activation of the AKT 275 
pathway by the insulin. Negative controls without the primary antibody were included 276 
in every trial to ensure the binding specificity. Insulin bioactivity was quantified by the 277 
ratio between phosphorilated and total AKT, on a per cell basis, expressed in 278 
percentage after incubation with the insulin released from ADS particles, as 279 
manufacture instructions. 280 
 281 
2.2.12. Circular Dichroism Spectroscopy 282 
Secondary structure of the released insulin from ADS particles before and after 283 
ultrasonication, as well as fresh standard insulin, was evaluated using CD. CD spectra 284 
were obtained with a Jasco J-720 spectropolarimeter (Tokyo, Japan) equipped with a 285 
temperature controller to examine the secondary structure of insulin in particles. Spectra 286 
were collected at 25°C using a 0.2 cm cell over the wavelength range of 200–260 nm. A 287 
resolution of 0.2 nm and scanning speed (50 nm/min) with a 4 s response time were 288 
employed. Each spectrum obtained represents an average of five consecutive scans. 289 
Noise reduction, blank buffer subtraction, and data analysis were performed using 290 
standard analysis and temperature/wavelength analysis programs (Jasco). Samples for 291 
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CD analysis were prepared by dissolution in isotonic PBS buffer (British 292 
Pharmacopoeia, 2010). The spectra of insulin samples with concentrations about 5 µM 293 
were compared with that of fresh insulin in the same medium. 294 
 295 
2.2.13. HPLC-MS  296 
HPLC-MS was used to investigate the chemical stability of released insulin from ADS particles 297 
throughout production, particles recovery and ultrasonication procedures. Samples were 298 
analyzed using a Liquid Chromatography of High Performance (Thermofinnigan) coupled to a 299 
quadrupole Ion Trap Mass Spectrometer (QIT-MS) system (LCQ, Advantage Max, 300 
Thermofinnigan, San Jose, CA), with an electrospray ionization (ESI) interface operated in the 301 
positive-ion mode. A C18 Reversed Phase column (150 × 2.1 mm; particle size: 3 µm; Waters 302 
Spherisorb ODS2) and a Guard Cartridge (4.6 × 10 mm; particle Size: 5 µm; Waters Spherisorb 303 
ODS2), kept at a temperature of 27˚C, were used for the separation. 304 
The mobile phase was composed by water (0.04% v/v trifluoroacetic acid):acetonitrile (0.04% 305 
trifluoroacetic acid), 80:20 v/v at a flow rate of 500 µL/min. A linear gradient of 20%–40% 306 
(acetonitrile 0.04% v/v trifluoroacetic) over 10 min was performed. An injection volume of 25 307 
µL of the samples was considered for the analysis. 308 
An insulin standard solution was prepared and considered as reference. Insulin samples 309 
for HPLC-MS analysis were prepared by dissolution in citrate sodium 55 mM prior to 310 
analysis. The XCALIBUR software package (Thermofinnigan) was used for data 311 
acquisition and analysis.   312 
 313 
2.2.14. Statistical Analysis 314 
Statistical analysis was performed using SPSS® Statistics (version 19, IBM® SPSS®). 315 
Size percentiles, mean particle size, zeta potential, recovery yield, insulin content and 316 
insulin bioactivity were represented using sample mean ± standard deviation (SD). 317 
Normality of the distributions of these variables was verified using Shapiro-Wilk test. 318 
Comparison between ultrasonication cycles was performed using one way analysis of 319 
variance (ANOVA). Post hoc comparisons were obtained using Tuckey’s test. 320 
Comparisons between insulin-loaded and unloaded conditions were obtained using 321 
student’s t test for independent samples when the underlying distribution was 322 
considered normal; Mann-Whitney’s test was used in the other situation. A significance 323 
of 0.05 was considered throughout the analysis. 324 
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 325 
3. Results and Discussion 326 
ADS particles were prepared by emulsification/internal gelation, which comprises the 327 
formation of an emulsion and internal gelation using high stirring speed. However, 328 
producing microgel with desired properties (especially narrow submicron size 329 
distribution with high encapsulation efficiency) is still a challenge. Several factors could 330 
affect size of microgel particles obtained by emulsification namely stirring speed, 331 
viscosity of both internal and external phases and recovery protocol.  Characterization 332 
of collected particles was made in relation to macroscopic features, recovery yield and 333 
insulin content. ADS particles showed that after rest at 4°C, they showed gel-like 334 
precipitate characteristic aspect, due to their high water content, according to their 335 
biopolymeric nature.  336 
The analysis and discussion of recovery yield, insulin content and particle size 337 
distribution will be done below. Further, the impact of ultrasonication on ADS particles 338 
will be evaluated in terms of size distribution, in physical stability by potential zeta 339 
measurements and sedimentation tests, and also in insulin bioactivity through in vitro 340 
studies.   341 
 342 
3.1.  Recovery Yield 343 
Extraction medium use coupled to centrifugation as recovery protocol, to attempt the 344 
extraction of ADS particles from the biphasic medium to the aqueous phase, was found 345 
to be around 50% and thus beneficial in terms of recovery yield (namely 49±14% and 346 
53±11% for insulin and unloaded particles respectively, with no significant difference). 347 
Remaining particles, not considered for this study, were collected only by the 348 
gravitational force, corresponding to the higher-sized particles and macroscopically 349 
visible aggregates. High recovery yield obtained with actual recovery protocol can be 350 
explained by the efficiency of the applied recovery medium and centrifugation force to 351 
remove particles from biphasic medium. This is especially important to the lower-sized 352 
particles, especially the desired submicron and NPs, which offer more difficulties to 353 
recover and to maintain segregated, within a polydisperse population characteristic of 354 
biopolymeric particles. Acetone/acetate buffer in 1:9 (v/v) as particles washing medium 355 
didn’t trigger any structural particles’ changes, like shape alterations confirmed by 356 
Cryo-SEM microphotographs (data not shown), whilst that occurred when a higher 357 
acetone proportion 4:6 (v/v) was used (Reis, Ribeiro, Neufeld & Veiga, 2007).  358 
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   359 
3.2.  Insulin Content  360 
Recovery protocol allowed obtaining around 57±6% of encapsulated insulin, lower than 361 
those reported previously (Reis, Ribeiro, Veiga, Neufeld & Damge, 2008). Insulin 362 
losses could have been due to particles’ stress during either their preparation or 363 
recovery. Firstly, during washing used to remove residue oil from the particles surface, 364 
insulin may has been drawn out of the particles following the extracted water, in which 365 
process probably smaller particles were more affected. Secondly, centrifugal force 366 
effect may have contributed also for insulin losses, due to porous nature of ADS 367 
particles. In the other hand, the presence of acetone may have caused some diffusive 368 
loss of encapsulated insulin owing to its dehydrating effect. Thus, the balance between 369 
insulin retention inside microgel and water extraction or/and centrifugal force use must 370 
be considered.  371 
  372 
3.3.  Size characterization (before and after ultrasonication cycles) 373 
During recovery of ADS particles, the appearance of aggregates was macroscopically 374 
observed. Aggregation is very common during nanoencapsulation especially when 375 
hydrophilic particles are obtained by emulsification. The higher stirring speed used to 376 
reduce mean particle diameter in the manufacture process causes a distribution of 377 
turbulent forces throughout the emulsion, which contributes to a higher heterogeneity of 378 
emulsion and consequently final microgel particles, resulting in particles with a wider 379 
distribution in size (Silva, Ribeiro, Figueiredo, Ferreira & Veiga, 2005). During 380 
emulsification and before gelation, samples were taken and observed under light 381 
microscopy and microphotographs showed emulsion droplets sizing higher than 1000 382 
nm and no existence of aggregation, as illustrated in Fig. 1. After that, and before 383 
recovery from biphasic medium, ADS particles prepared by emulsification/internal 384 
gelation remained spherical and discrete but some particles larger than 1000nm and 385 
aggregates were formed (data not shown). 386 
On the other hand, insulin (pI≅5.4) and both alginate and dextran sulfate show opposite 387 
charges, allowing interaction through electrostatic interactions. These physical surface 388 
charges contribute to particles’ network; however they do contribute also to 389 
aggregation, owing to their great affinities. Aggregation was potentiated also due to 390 
particle adhesion, especially under van der Waals forces (Nguyen, Rouxel, Hadji, 391 
Vincent & Fort, 2011). 392 
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Recovery medium, composed by acetate buffer and acetone, promoted high mobility to 393 
larger particles and aggregates primarily recovered by sedimentation. Particles dispersed 394 
in the remaining biphasic medium were theoretically smaller, and thus more difficult to 395 
extract. Centrifugation force applied to particles recovery in the presence of the washing 396 
medium could allow the recovery of the remaining and lower size particles of the 397 
biphasic medium. As the composition of the washing medium used in the washing 398 
cycles to remove the residual oil before the recover protocol was constant among 399 
recovery cycles, aggregation seemed to be triggered by aftermost particle handling 400 
conditions.  401 
Size distribution of insulin particles is shown in Fig. 2(a) in terms of volume. Insulin 402 
diameter values corresponding to percentils of 10%, 50% and 90% and also span value 403 
are depicted in Table 1. Regarding ADS particles’ size distribution, it was divided into 404 
two ranges: one range was constituted of NPs and low-sized microparticles (< 4 µm), 405 
and the main range was constituted of higher-sized microparticles (d90% = 144.8±30.45 406 
µm). Therefore, unloaded particles, after recovery, showed a wide size distribution as 407 
expected, with the predominant percentage of microparticles probably due to the 408 
presence of aggregates and a lower percentage of low-sized particles (Table 1). 409 
As it had been said before, particles’ size-fractioning using recovery medium coupled to 410 
centrifugation promoted enhancement of particles extraction from biphasic medium, 411 
indicated by a significant recovery yield percentage value (~50%). However, it can 412 
probably simultaneously had contributed to parallel aggregation phenomena due to high 413 
ultracentrifugation forces.  414 
With respect to percentage of smaller particles, namely within nano- and submicron 415 
range (<1000nm), it was possible to observe through the values of percentils a large 416 
increase between d10% (364 ±124 nm) and d50% (26.16±3.89 µm) values, exposing the 417 
existence of a very low percentage of low-sized particles, according to size distribution 418 
analysis, which reinforces the obstacle in obtaining and recovering discrete submicron 419 
microgel particles by emulsification. Though in low percentage, the presence of NPs 420 
was confirmed by Cryo-SEM microphotographs, which depict their presence (data not 421 
shown). Moreover, as lower-sized particles are lighter, recovery medium together with 422 
centrifugation may not have been completely successful and some particles may have 423 
been retained in the emulsified and non-aqueous phase.   424 
Hereupon, as size-fractionation of microgel particles led to unwanted aggregation 425 
phenomena, a strategy was searched to minimize particle aggregation and to allow a 426 
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better ADS particles size characterization. Sonication is routinely included in particle 427 
dispersion being applied to produce uniform-sized alginate nanocapsules 428 
(Lertsutthiwong, Noomun, Jongaroonngamsang, Rojsitthisak & Nimmannit, 2008) and 429 
polyelectrolyte coated NPs (Zheng, Zhang, Carbo, Clark, Nathan & Lvov, 2010). This 430 
technique was chosen as an attempt to eliminate or decrease particles’ aggregation and 431 
therefore to allow a narrower particle size distribution. Two five-minute ultrasonication 432 
cycles were performed in the particles-containing suspensions to ascertain its effect on 433 
particle size distribution, which was evaluated in separate by size-measurements by LD. 434 
Fig. 2(b) shows the size distribution of ADS particles after the first ultrasonication 435 
cycle. After this first exposure, insulin particles moved to a predominantly submicron 436 
and micron ranges, depicted by a notable deviation to the left of the distribution curve in 437 
relation to initial profile in Fig. 2(a), in particular for the nanoscale. This lead to a 438 
significant decrease of percentile percentage values as we can see in Table 1, and 439 
consequently the percentage of higher-size particles decreased substantially. After the 440 
second ultrasonication cycle, there were no significant differences in size distribution 441 
behaviour. In this study, there were no differences also between insulin and unloaded 442 
particles about size distributions (data not shown). As LD technique allows a wide size 443 
range (0.040–2000 µm), exposed to ultrasonication samples, which were previously 444 
determined to be in the absence of higher-sized microparticles, were also analysed by 445 
Dynamic Light Scattering (DLS). This last technique shows reliable scope analysis up 446 
to 1000nm, and the results for ultrasonicated samples were consistent with the results 447 
given above by LD, namely 793 ± 71 nm of mean particle size and 0.37 of PI. This 448 
confirmed the existence and predominance of NPs in ADS particles populations after 449 
ultrasonication. Like in the present experiment, a 30-second ultrasonication cycle of 450 
antigen-alginate particles significantly reduced the mean diameter, size range and their 451 
percentage over 10µm, but increasing the sonication time, there were no significant 452 
changes (Ghiasi, Sajadi Tabasi & Tafaghodi, 2007). 453 
Ultrasonication may have disaggregated particles in some extension but there were 454 
probably irreversible aggregates that remain unchanged. In turn, span values, in Table 1, 455 
were reduced after ultrasonication exposure, confirming once more the enhancement of 456 
lower-sized particles after ultrasonication, but it still remains the necessity for 457 
optimizing towards nanoscale applications.  458 
ADS particles exhibited a roughly spherical shape with smooth surface which is 459 
characteristic of these particles (Reis, Ribeiro, Houng, Veiga & Neufeld, 2007), and it 460 
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was not altered by ultrasonication exposure, as we can see through Cryo-SEM 461 
microphotographs, in Fig. 3. Their qualitative analysis provided by mass spectroscopy 462 
confirmed these observations, through the existence of tungsten, used to stain negatively 463 
particles (data not shown). 464 
Centrifugation of microgel dispersed in acetate buffer as a strategy to explore particles’ 465 
size-fractioning revealed unwanted aggregation, which was not prevented or reversed. 466 
In this context, ultrasonication approach to decrease aggregation phenomena minimized 467 
this obstacle.  468 
 469 
3.4.  In vitro release  470 
Premature insulin release in the stomach can result in acidic and enzymatic degradation, 471 
however release in the intestinal mucosa may improve insulin uptake and translocation 472 
through the gastrointestinal tract (Woitiski, Neufeld, Ribeiro & Veiga, 2009). Fig. 4 473 
depicts the release profile of ADS particles under simulated gastric and intestinal 474 
conditions. At low gastric pH, no insulin was released from ADS particles, however 475 
after the transition to intestinal pH, insulin started to be burst released, up to 4 hours, 476 
and then it has maintained release profile, achieving a maximum of ~ 75% of 477 
cumulative released insulin after 10 hours. The amount of insulin retained within 478 
nanoparticles under intestinal simulation may be tightly bound to the alginate nucleus, 479 
so a more extensive dissolution for additional release may be needed (George & 480 
Abraham, 2006). 481 
 These results demonstrate insulin retention within the particles’ core during gastric 482 
environment. Once in the intestinal tract, encountering neutral pH, the alginate networks 483 
forming the NPs’ core swell due to deprotonation becoming increasingly permeable to 484 
insulin (Woitiski, Neufeld, Veiga, Carvalho & Figueiredo, 2010), releasing it to the 485 
medium.  Insulin release from ADS particles is pH dependent, with a continuous release 486 
profile, indicating ADS particles as an effective controlled delivery system for insulin.  487 
 488 
3.5. Physical stability 489 
Physical stability of ADS suspensions was evaluated through zeta potential 490 
measurements and sedimentation tests before and after ultrasonication exposure.  491 
Zeta potential values varied between -25.7 and -31.9 mV, and no significant effect of 492 
Ultrasonication on zeta potential values was detected, as we can see in Table 1, pointing 493 
to the absence of physical stability changes after ultrasonication. Negative zeta potential 494 
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values are a result of surface charges, namely anionic alginate and dextran sulphate 495 
chains at pH 4.5. and similar results were obtained for microgel made of similar 496 
biopolymers (Reis, 2007). ADS particles presented higher stability than alginate-497 
composed nanospheres, because dextran sulfate assembly conferred higher stability to 498 
particle matrix due to higher charge density.   499 
The analysis of separation under accelerated conditions is a useful guide in NPs 500 
formulation, minimizing on long-term stability testing and allowing an early detection 501 
of gravitational sedimentation problems. Insulin ADS particles analysis results, before 502 
and after ultrasonication, can be seen in Fig. 5 and Fig. 6, respectively. A similar 503 
behaviour for insulin and unloaded particles was observed, so only insulin ADS 504 
particles profiles are shown. 505 
The analysis of the transmission profiles of ADS particles revealed a marked change in 506 
demixing behaviour before and after ultrasonication treatment. Starting with the 507 
analysis of the particles before of the ultrasonication, if it is considered for instance, the 508 
position 116 mm (the middle of the cell) in Fig. 5, the first profile was recorded at 509 
~50% being the last profile, at about 90% of transmission, achieved by a fast increase of 510 
transmission (as it can be seen from the accumulation of the green last profiles in the 511 
top). Around 123 mm position (the bottom of the cell), the transmission percentage 512 
sudden drops as a result of the presence of aggregates which had accumulated in the 513 
bottom. This is observed since the beginning of the test (represented by the first 514 
recorded red profile in the graph), denouncing that these particles easily deposit, 515 
representing a characteristic transmission profile of an aggregated sample. With the 516 
advance of the centrifugation time, the height of the pellet decreases, indicating that 517 
settled particles aggregated with each other after their deposition. This marked demixing 518 
behaviour was also observed macroscopically. The initial sample was a homogenous 519 
suspension, in which particles were supposedly homogeneously distributed in the 520 
suspension. At the end of the sedimentation test, it was observed a clear supernatant at 521 
the top and a turbid pellet in the bottom of the cell, results of demixing process, in 522 
accordance to the higher final transmission.   523 
Submitting these particles to ultrasonication, samples acquire a characteristic dispersion 524 
profile instead of an aggregated one, where particles are smaller, shown in Fig. 6. The 525 
same transmission behaviour was shown for the almost whole sample length, with no 526 
significant demixing process. Little fluctuations were visible, which indicates a more 527 
homogenous sample in size than the previous one. Comparing both transmission 528 
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profiles, before ultrasonication, shown in Fig. 5, a higher transmission was occurred 529 
because the larger particles showed a higher separation in the same first interval than in 530 
after ultrasonication, in Fig. 6, which showed a lower transmission. It had probably 531 
occurred also an accumulation of lower-sized particles in the top of the sample, which 532 
was no observed before ultrasonication exposure. These were probably lighter particles 533 
of lower size that resulted from the breakdown of aggregates by the use of 534 
ultrasonication. A reduced accumulation of particles in the bottom was seen in Fig. 6, 535 
representing the existence of larger particles; but with remarkable difference of 536 
aggregation extent than initial untreated samples as shown in Fig. 5. After 537 
ultrasonication sample, it was visible a lower final transmission, shown in Fig. 6, 538 
accompanied with a macroscopically bit turbid along the length of the sample when 539 
visually inspected after removal from the rotor. These last particles’ populations showed 540 
slower particles than before ultrasonication one, due to smaller size and/or smaller 541 
density difference to the continuous phase (acetate buffer). These results sustain the 542 
previous analysis of particles’ size, as well as an increased physical stability after 543 
ultrasonication relatively to initial conditions in accordance to zeta potential 544 
measurements.  545 
When the suspension is not stabilized enough, particles can regroup back after 546 
ultrasonication(Reis, Ribeiro, Neufeld & Veiga, 2007). Sedimentation tests of the same 547 
ultrasonicated samples were repeated after one week, and no differences were found 548 
between «fresh» ultrasonicated ones, shown in Fig. 6, and one-week-after recorded 549 
transmission profiles (data not shown). These results suggest that particles maintain its 550 
stability for at least one week after ultrasonication treatment.   551 
Thus, zeta potential analysis suggests ADS particles as physically stable systems before 552 
and after ultrasonication exposure. These results were complemented by information 553 
given by sedimentation tests, indicating that after ultrasonication all samples become 554 
even more stable than the previous ones. 555 
 556 
3.6. Protein bioactivity   557 
Preservation of the structural integrity of a protein drug during manufacture is crucial 558 
for its biological efficacy. Thus, the secondary structure of insulin extracted from ADS 559 
particles was assessed by measuring the extent of phosphorylation of intracellular AKT, 560 
since AKT phosphorylation is a downstream event triggered by the binding of active 561 
insulin to its receptors on the cell surface (Elghazi, Balcazar & Bernal-Mizrachi, 2006). 562 
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Fig. 7 shows the activity of extracted insulin before and after ultrasonication. Biological 563 
activity of insulin extracted from collected particles was between 60-80%.  564 
The remaining low percentage of insulin bioactivity was possibly due to losses during 565 
both preparation and recovery since emulsification/internal gelation comprises various 566 
steps critical for biological activity stability of insulin. First, during formation of the 567 
water/oil (w/o) emulsion, insulin can be affected by the w/o solvent interface. Interfacial 568 
adsorption can be followed by unfolding which results in reduced biological activity. 569 
Upon emulsification of an aqueous solution of ʟ-aspariginase into an organic solvent a 570 
substancial decrease in enzyme activity was reported. Consequently, the contact with 571 
lipophilic interfaces provoked denaturation, but insoluble aggregates were not formed 572 
(Wolf, Wirth, Pittner & Gabor, 2003). 573 
A slight change of the insulin’s secondary structure (native conformation) was found 574 
after encapsulation and recovery processes by similar protocols (Reis, Ribeiro, Houng, 575 
Veiga & Neufeld, 2007). A possible explanation is that insulin could be linked to 576 
particle’s polymers network which can alter protein structure, though not representing 577 
denaturation or loss of insulin activity.  578 
Previous results obtained with insulin alginate particles prepared by a similar procedure 579 
showed that 55% of insulin retained activity quantified by Western Blot, leading to 580 
assume that emulsification/internal gelation is capable of retain particles’ insulin 581 
bioactivity (Reis, Ribeiro, Houng, Veiga & Neufeld, 2007). Therefore, neither the 582 
emulsification nor the proposed recovery protocol showed a specific impact on insulin 583 
bioactivity.    584 
Another source of inactivation during ADS particles’ preparation is cavitation stress as 585 
necessary for disaggregation of NPs. Despite cooling, ultrasonication provokes 586 
cavitations with local extremes of temperature and radical formation which adversely 587 
affect proteins. As we can see in Fig. 7, submicron particles showed no insulin 588 
bioactivity alterations after ultrasonication, even exhibiting a larger surface area to 589 
volume ratio in comparison to the higher-sized ones predominant in untreated ADS-590 
particles. Ultrasonication employed in the disaggregation of particles is expected to 591 
affect insulin integrity. This could be a risk due to the closer localization of the insulin 592 
to the particle surface and higher susceptibility to suffer a greater damage in relation to 593 
the protein located in the core of the bigger particles. However, like the present results, 594 
insulin NPs were prepared by the Layer-by-Layer adsorption of polyelectrolytes after an 595 
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ultrasonication for several minutes and no insulin damage was reported (Fan, Wang, 596 
Fan & Ma, 2006).  597 
These results suggest the possibility of ultrasonication use in polydisperse particles 598 
populations, without the risk of smaller sized particles damage in relation to insulin 599 
bioactivity. Thus, insulin ADS particles constitute a carrier with maintenance capacity 600 
of encapsulated insulin bioactivity retention after recovery, handling and ultrasonication 601 
exposure.   602 
 603 
3.7.  Circular Dichroism  604 
  605 
Preservation of the structural integrity of a protein drug is important for its biological 606 
efficacy, so the secondary structure of insulin released from ADS particles was 607 
investigated using CD in the far UV region. Results depicted in Fig. 8 show the CD 608 
spectra of fresh diluted insulin reference solution (non-encapsulated), and released 609 
insulin from ADS particles before and after ultrasonication. Insulin reference solution in 610 
PBS at pH 7.4 showed typical bands with two minima at approximately 209 and 222 611 
nm, indicating the presence of major α-helix structure with part of β–sheets. 612 
CD spectrum of released insulin before ultrasonication show that, besides the presence 613 
of the major minimum at 209nm, the minor minimum at 222nm decreased significantly 614 
in magnitude (appearing only a slight depression), indicating insulin suffered changes in 615 
relation to the reference insulin. These results suggest that the secondary structure of 616 
insulin (native conformation) after encapsulation into ADS particles and recovery 617 
processes was changed. In the process of ADS particles production, it is known that 618 
polymers binding may have caused conformational changes to insulin structure, which 619 
normally are detected in CD spectra (Wallace, 2009); moreover, the higher exposition 620 
of protein to air/liquid or liquid/solid interfaces, like stirring and centrifugation could be 621 
factors that have determined these changes.   622 
In released insulin after ultrasonication CD spectrum, 209nm minimum suffered a 623 
decrease in magnitude and 222nm minimum has been shifted to 217nm, which points to 624 
enhancement of β–sheets proportion. This is in accordance to previous studies, where 625 
sonication of proteins with substantial content in helical structure in the native state, like 626 
insulin (Jimenez, Nettleton, Bouchard, Robinson, Dobson & Saibil, 2002), caused an 627 
increase in β-structure with a concomitant decrease in α-helical structure (Stathopulos, 628 
Scholz, Hwang, Rumfeldt, Lepock & Meiering, 2004). In fact, metmyoglobin, showed 629 
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that under stress conditions, such as low temperature and high pressure conditions, was 630 
only partially unfolded, with a rigid core consisting of helices remaining folded 631 
(Matsuo, Sakurada, Yonehara, Kataoka & Gekko, 2007; Meersman, Smeller & 632 
Heremans, 2002). In the present experiments, besides the existence of CD spectra 633 
changes, it can be concluded, together with the previous in vitro experiments results and 634 
HPLC-MS analysis, that insulin was not chemically modified but has suffered a 635 
substantial conformational change, as it was exposed by handling conditions, namely 636 
after production and recovery, and also after ultrasonication.  637 
In both cases, before and after ultrasonication, released insulin suffered conformational 638 
changes from helical structures to β–sheets. This phenomenon occurs differently to 639 
proteins with predominantly β-features in native CD spectra which show spectral 640 
changes upon sonication less pronounced, and there is little apparent change in 641 
secondary structure (Jimenez, Nettleton, Bouchard, Robinson, Dobson & Saibil, 2002), 642 
which suggests further biological activity analysis (Corrêa & Ramos, 2009; Kelly, Jess 643 
& Price, 2005).  644 
Thus, together to in vitro biological activity results as well as the presence of no 645 
aggregates as confirmed by HPLC-MS, detected changes in insulin secondary structure 646 
cannot be considered as meaningful, being common in released peptide and protein 647 
samples (Al-Tahami, Oak & Singh, 2010; Zhang et al., 2010) and thus do not 648 
representing loss of biological activity. 649 
 650 
3.8.  HPLC-MS 651 
Insulin is susceptible to several chemical modifications, and the most common reactions 652 
that can occur are deamidation, acylation and peptide bond cleavage (Oak & Singh, 653 
2011). Maintaining protein stability during processing is critical in providing safe and 654 
efficacious protein therapeutics with long shelf lives (Reis, Ribeiro, Neufeld & Veiga, 655 
2007), so HPLC-MS was applied to determine the stability of insulin. The HPLC-MS 656 
chromatograms of reference insulin solution and insulin extracted from ADS particles 657 
were similar as shown in Figure 9 (a) and (b), as well as occurred in the case of 658 
reference insulin and insulin extracted from ADS particles after ultrasonication 659 
exposure (data not shown). HPLC-MS analysis showed that no high molecular weight 660 
transformation products were formed, such as covalent dimmers. So, 661 
emulsification/internal gelation procedure, recovery protocol and ultrasonication used to 662 
reduce ADS particle size don’t affect insulin chemical stability. 663 
Page 21 of 36
Ac
ce
pte
d M
an
us
cri
pt
21 
 
 664 
 665 
4. Conclusions 666 
Size-fractioning of microgel obtained by emulsification showed the presence of high 667 
percentage of aggregates. Submitting these particles to ultrasonication allowed the 668 
transition from a multimodal and polydisperse population to a more homogeneous and 669 
less polydisperse population, where the nanometric scale stands, contrary to initial 670 
conditions. This behaviour is sustained by the deviation of the size distribution profile 671 
from the micrometric range to the nanometric range and the decrease of respective span 672 
values. The use of one ultrasonication-cycle in performed conditions was beneficial to 673 
reduce aggregation in these particles, without compromising biological insulin activity 674 
and colloidal stability. This entails the necessity to size-segregate these populations, in 675 
order to homogenize and standardize different obtained populations to attain a specific 676 
and physiological action that is not particularly related to a smaller size. Significant 677 
recovery yield, insulin content, shape and surface conservation, as well as preservation 678 
of bioactivity of insulin were obtained after all recovery and handling, ADS particles 679 
recovered by the use of a recovery medium constituted by acetone and acetate buffer 680 
coupling to centrifugation constitute a good strategy to obtain particles with reversible 681 
aggregation. This phenomenon is reversed in some extent by the use of ultrasonication 682 
without biological and physicochemical risks in performed conditions. However, 683 
despite ultrasonication is known to have good disaggregation capacities, insulin 684 
secondary structural changes were detected in CD spectra, leading to the necessity of 685 
further studies by highly sensitive spectroscopic methods, such as deconvolution of 686 
synchrotron radiation circular dichroism and fourier transform infrared spectroscopy 687 
spectra if quantitative evaluation is required. Moreover, facing the necessity of solvents 688 
use to yield ADS particles recovery, the absence of isopropanol and hexane, as in 689 
previous studies, is a beneficial factor in relation to health and environmental issues 690 
increasing this technique potential implementing. In doing so, further ultrasonication 691 
approaches for ADS particles with well-established and reproducible conditions will be 692 
desired, to get stable and narrower populations within submicron range. This stage is 693 
indispensible since the application of these particles in vivo depends on size and 694 
polydispersity-dependent factors, namely the recently established protein corona, 695 
capable of determine the dissolution profile, interaction and membranes crossing, 696 
absorption, distribution, targeting and insulin biological effects. 697 
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LIST OF FIGURES 823 
 824 
Fig. 1 - Optical microphotograph of system droplets during emulsification of 825 
manufacture process (1000×). Samples were died with Victoria-blue R. 826 
 827 
Fig. 2 – Particle size distribution profile of ADS particles: (a) particles are mainly 828 
distributed in the micrometric range, owing to the presence of higher-sized particles and 829 
aggregates. (b) After one five-minute cycle of ultrasonication exposure, there was a 830 
narrower particle size distribution mainly composed by NPs. The second five-minute 831 
cycle of ultrasonication didn’t introduce any significant changes. 832 
 833 
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Fig. 3 – Insulin ADS particles after one sonication-cycle, by Cryo-SEM (25000x, 15kV, 834 
WD=15mm). Ultrasonication allows obtaining a low disperse population. Characteristic 835 
core-shell shape of these particles is easily observable through 3D visualization.  836 
 837 
Fig. 4 – In vitro release profile of ADS particles in simulated gastric medium at pH 1.2 838 
followed intestinal medium at pH 6.8, depending on time. Results are means ± SD of 839 
three experiments. 840 
 841 
Fig.  5  – Recorded evolution (from red to green colour) of time dependent transmission 842 
profiles of insulin ADS particles, depicting a characteristic profile of an aggregated 843 
sample with clear demixing behaviour. Profiles were taken every 30 s at 2000 rpm 844 
during 128 minutes. X-axis represents the position of the rotor.  845 
 846 
Fig. 6 – Recorded evolution (from red to green colour) of time dependent transmission 847 
profiles of insulin loaded-alginate-dextran sulfate particles after ultrasonication, 848 
revealing a characteristic dispersion profile, where particles were smaller and less 849 
polydisperse. Profiles were taken every 30 s at 2000 rpm during 128 minutes. X-axis 850 
represents the position of the rotor. 851 
 852 
Fig. 7 – Bioactivity of insulin contained in ADS particles before and after 853 
ultrasonication by FACE™ AKT ELISA assay (mean ± SD; n = 3). ADS particles 854 
showed high bioactivity retention, which was maintained after ultrasonication exposure 855 
indicated by no significant differences (considering significant difference for p value 856 
less than 0.05, n=3). 857 
 858 
Fig. 8 – CD spectra of insulin in solution (5 µM) in PBS at pH 7.4 and 25°C: (solid line)  859 
insulin non-encapsulated (reference solution), (dashed line) insulin released from ADS 860 
particles before ultrasonication and (dotted line) insulin released from ADS particles 861 
after ultrasonication exposure. 862 
 863 
Fig. 9 – HPLC-Mass representative chromatograms of reference solution of: (a) insulin 864 
non-encapsulated (reference solution) and (b) insulin released from ADS particles, both 865 
before ultrasonication exposure.  866 
 867 
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Table 1. Particle Size Analysis and Zeta Potential of ADS particles before and after 868 
Ultrasonication Exposure  869 
 870 
 d10% (µm) d50%(µm) d90%(µm) 
Span 
value 
Zeta Potential 
(mV) 
Insulin ADS particles 0.364±0.124 26.16±3.89 144.8±30.45 5.521 -31.9±1.4 
1 ultrasonication cycle 
exposed insulin ADS 
particles 
0.114±0.062 0.352±0.101 1.803±0.182 4.798 -26.2±1.2 
2 ultrasonication cycles 
exposed insulin ADS 
particles 
0.203±0.054 0.425±0.088 2.051±0.167 4.348 -25.7±1.5 
Unloaded ADS particles 0.534±0.172 28.53±9.69 164.7±29.94 5.754 -30.3±1.1 
Diameter values corresponding to percentiles of 10%, 50%, and 90%, zeta potential (mean ± SD, 871 
n=3) and span value of insulin ADS particles before and after being exposed to one and two five-872 
minute ultrasonication cycles.      873 
a Significant difference with a p value of less than 0.05 was verified between before and 874 
after being exposed to both 1 and 2 ultrasonication cycles.  875 
b There was no difference between 1 and 2 ultrasonication cycle expositions.  876 
 877 
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Highlights  878 
• A recovery protocol was applied to obtain narrower hydrogel particles’ 879 
populations 880 
• Size-fractioning of hydrogel particles shows high aggregation degree  881 
• Ultrasonication reverses particles’ aggregation and homogenizes populations 882 
• Insulin bioactivity is maintained after ultrasonication exposure 883 
• Particles dispersed in aqueous medium show good stability after ultrasonication  884 
 885 
 886 
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